There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Yahoo Finance discussed the stock recently as it posted Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia.
As a NASDAQ listed company, SRRK falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Scholar Rock Holding Corp is $1.08B. A total of 0.65 million shares were traded on the day, compared to an average of 902.50K shares.
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, SRRK has seen 1 BUY and 1 SELL insider trades, representing the acquisition of 5,339 and the disposition of 291,906 shares. Over the last 12 months, there were 10 BUYs and 7 SELLs from insiders. Insiders purchased 6,923,889 shares during that period but sold 345,733.
In the most recent transaction, Myles Edward H sold 6,634 shares of SRRK for 15.93 per share on Jan 16. After the transaction, the COO & CFO now owns 162,150 company shares. In a previous transaction on Jan 16, Ho Junlin sold 4,186 shares at 15.93 per share. SRRK shares that GENERAL COUNSEL owns now total 154,405.
Among the insiders who sold shares, Parlavecchio Caryn disposed of 2,849 shares on Jan 16 at a per-share price of $15.93. This resulted in the CHRO holding 114,350 shares of SRRK after the transaction. In another insider transaction, Qatanani Mo sold 2,002 shares at $15.93 per share on Jan 16. Company shares held by the SVP AND HEAD OF RESEARCH now total 78,816.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for SRRK in the last 3 months, the mean price target is $25.71 with high estimates of $30.00 and low estimates of $20.00. In terms of 52-week highs and lows, SRRK has a high of $21.17 and a low of $5.56.
As of this writing, SRRK has an earnings estimate of -$0.49 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.45 per share and a lower estimate of -$0.54. The company reported an EPS of -$0.47 in the last quarter, which was 14.50% higher than expectations of -$0.55.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. SRRK’s latest balance sheet shows that the firm has $252.99M in Cash & Short Term Investments as of fiscal 2021. There were $77.06M in debt and $64.30M in liabilities at the time. Its Book Value Per Share was $2.98, while its Total Shareholder’s Equity was $172.07M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for SRRK is Buy with a score of 5.00.